IC 31 seasonal influenza vaccine - CSL/Valneva

Drug Profile

IC 31 seasonal influenza vaccine - CSL/Valneva

Alternative Names: IC31® Flu vaccine - CSL/Valneva; Seasonal trivalent influenza vaccine (Agrippal® + IC31®) - CSL/Valneva

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Intercell; Novartis
  • Developer CSL; Valneva
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Influenza virus infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Influenza-virus-infections(Prevention) in Austria (IM, Injection)
  • 28 May 2013 Seasonal influenza prophylactic vaccine is still in phase I trials for Influenza virus infections in Austria
  • 28 May 2013 Intercell has merged with Vivalis to form Valneva
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top